MorphoSys AG

NasdaqGS:MOR Stock Report

Market Cap: US$2.8b

MorphoSys Future Growth

Future criteria checks 2/6

MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.

Key information

59.1%

Earnings growth rate

78.18%

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth rate25.0%
Future return on equity7.68%
Analyst coverage

Good

Last updated05 Aug 2024

Recent future growth updates

Recent updates

Seeking Alpha • May 01

MorphoSys: Hold Rating Until The Novartis Deal Closes

Summary MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals received and successful precedents of similar M&A transactions. Pelabresib, MorphoSys's leading candidate for myelofibrosis treatment, shows promising results and potential as a game-changer in the field. We downgrade to a hold rating, although, we believe the deal will close in 1H 2024. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Novartis And MorphoSys Are A Perfect Match

Summary Novartis plans to acquire MorphoSys, a German biopharmaceutical company, for EUR 2.7 billion in cash. The acquisition will give Novartis access to MorphoSys' extensive oncological pipeline, including the potentially game-changing treatment option for myelofibrosis, pelabresib. Novartis has a strong financial position and the capacity to comfortably fund the acquisition, demonstrating its readiness to enhance its oncology portfolio. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Summary Shares of biotech company MorphoSys have been climbing due to the approval chances of its lead candidate, pelabresib, for the treatment of myelofibrosis. MorphoSys co-markets and sells the drug Monjuvi in the US, which is used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma. Despite some mixed data and intense competition, analysts believe pelabresib could reach peak annual sales of over $1.5 billion, which would significantly increase MorphoSys' valuation and share price. The Munich based biotech took a substantial risk to acquire Constellation Pharma, developer of Pelabresib, in a $1.7bn deal. After a torrid bear run on the stock, MorphoSys may finally be ready to deliver upside in 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

MorphoSys updates Q2 & FY22 guidance below prior provided levels

MorphoSys (NASDAQ:MOR) trades 12.8% down premarket after it provided updated financial guidance based on prelim consolidated results for the first six months 2022 and post the recent licensing agreements with Human Immunology Biosciences for felzartamab and MOR210. Preliminary Monjuvi (tafasitamab-cxix) U.S. Net Product Sales stood at $23.3M (€21.7 million) for Q2 of 2022 and $41.9M (€38.3M) for 1H22. For FY22, MorphoSys now expects Monjuvi U.S. Net Product Sales in the range of $90 to $110M (previously: $110 to $135M). It sees R&D expenses in the range of €275 to €300M (previously: €300 to €325M) and SG&A expenses in the range of €150 to €165M (previously: €155 to €170M). Guidance for Gross Margin for Monjuvi U.S. Net Product Sales remains unchanged. The previous financial guidance for 2022 was provided by MorphoSys on Jan. 7, 2022 and reaffirmed on Mar. 16 2022 and May 4, 2022.
Seeking Alpha • May 04

MorphoSys May Not Recover From Adventurous Constellation Buyout

MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly.
Seeking Alpha • Jan 28

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Sierra Oncology got a boost on Monday, releasing some very strong data in relation to its lead asset Momelotinib. The drug - indicated for Myelofibrosis - looks like it can match standard of care Jakafi, and improve upon the latter's record amongst patients suffering with anemia. If approved, although it will take time, Sierra may have a blockbuster drug (>$1bn sales per annum) on its hands. Meanwhile, Morphosys stock has had a tough time ever since the German biotech acquired Constellation to get hold of its BET inhibitor Pelabresib - indicated for Myelofibrosis. Morphosys has co-developed a drug - Monjuvi - with Incyte, who market and sell Jakafi - in combo with Pelabresib, Jakafi may be able to resist the challenge from Momelotinib.

Earnings and Revenue Growth Forecasts

NasdaqGS:MOR - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026425-78-120-505
12/31/2025322-140-236-2018
12/31/2024180-249-296-2533
3/31/2024241-469-286-284N/A
12/31/2023238-190-299-296N/A
9/30/2023223104-363-355N/A
6/30/2023255100-349-338N/A
3/31/2023261-61-321-306N/A
12/31/2022278-151-382-367N/A
9/30/2022250-861-436-417N/A
6/30/2022195-851-606-588N/A
3/31/2022174-596-610-583N/A
12/31/2021180-514-508-481N/A
9/30/2021163-150-423-393N/A
6/30/2021143-103-295-246N/A
3/31/2021124-177-255-217N/A
12/31/202032898-1435N/A
9/30/2020303642663N/A
6/30/202029310598113N/A
3/31/2020309153137152N/A
12/31/201972-103-85-81N/A
9/30/201971-96-68-64N/A
6/30/2019114-42-42-39N/A
3/31/201987-59-33-31N/A
12/31/201876-56-35-33N/A
9/30/201894-27-16-14N/A
6/30/201854-82-61-48N/A
3/31/201858-74-68-55N/A
12/31/201767-70N/A-38N/A
9/30/201752-84N/A-52N/A
6/30/201749-73N/A-59N/A
3/31/201749-68N/A-47N/A
12/31/201650-60N/A-47N/A
9/30/201649-45N/A-48N/A
6/30/201648-40N/A-41N/A
3/31/201648-33N/A-35N/A
12/31/201510615N/A-24N/A
9/30/201511127N/A-15N/A
6/30/201511633N/A-3N/A
3/31/201511937N/A-4N/A
12/31/201464-3N/A-14N/A
9/30/201461-6N/A-15N/A
6/30/201460-5N/A79N/A
3/31/2014777N/A76N/A
12/31/2013787N/A89N/A
9/30/20138014N/A100N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOR's revenue (25% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 18:56
End of Day Share Price 2024/08/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MorphoSys AG is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olav ZilianBaader Helvea Equity Research
Brian BalchinBarclays
Rosie TurnerBarclays